tumsasedgars / iStockphoto.com

8 June 2018Americas

BIO 2018: Allergan-tribe deal just the start, says former USPTO director

“The Saint Regis Mohawk Tribe issue is not unique to just life sciences—we’re likely to see it across the board. There’s likely been other transfers that are not yet public information,” said Teresa Rea, vice-chair of Crowell & Moring’s IP group and former director of the US Patent and Trademark Office (USPTO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent